ABHD17C and cancer: Analysis of the Cancer Therapeutics Response Portal (CTRP) revealed that ABHD17C expression was significantly correlated with cellular resistance against ferroptosis inducers, including RSL3, ML210, and ML162 (Figure6A), suggesting that ABHD17C might function as a ferroptosis suppressor.